United Therapeutics (NASDAQ:UTHR) finance chief Edgemond James disclosed sales of company stock totaling $5.7 million on April 16, 2026. The transactions comprised 10,000 shares of Common Stock, executed at prices between $573.9146 and $581.64, according to the filing reported for that date.
Also on April 16, James exercised stock options covering 10,000 shares at an exercise price of $135.42, for a stated total value of $1354199. The insider activity was carried out under a Rule 10b5-1 trading plan, the filing notes.
At the time of the transactions, United Therapeutics shares were trading close to their 52-week high of $607.89 and had appreciated about 104% over the prior 12 months. Independent analysis cited in the report indicates the stock was trading at $588.38 and appeared overvalued relative to its Fair Value assessment.
Company developments and analyst actions
The filing and related disclosures come alongside several operational and clinical updates for United Therapeutics. The U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy designation to miroliverELAP, an investigational liver assist device developed by Miromatrix Medical Inc., a subsidiary of United Therapeutics. The device is intended to provide temporary liver support for patients with acute liver failure.
Separately, the company’s Tyvaso program for idiopathic pulmonary fibrosis has been a focal point for analysts. H.C. Wainwright raised its price target to $660, Jefferies lifted its target to $733, and BofA Securities adjusted its target to $626 following favorable trial results. Raymond James initiated coverage with an Outperform rating and set a $700 price target, noting the potential for Tyvaso to generate strong peak sales. These analyst moves and the FDA designation were highlighted alongside the insider transactions in the company disclosures.
Context and limits
The filing specifies that the trades were made pursuant to a pre-established Rule 10b5-1 trading plan. The documents also reflect the market context at the time of the trades, including recent share-price performance and third-party valuation commentary. Beyond those disclosures, the filing does not provide additional commentary on the motivations for the purchases or sales, nor does it project future company performance.